BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation announced today that EKOS and their Netherlands distributor, AngioCare BV, are supporting a Dutch multicentre randomized trial (DUET) designed to ...
Randomized Controlled Multi-Center Trial Demonstrates Reduced Treatment Time and Drug Dose with EKOS vs. Catheter-Directed Thrombolysis in Peripheral Arterial Occlusions EKOS Corporation, a privately ...
Ekos, a Bothell medical device maker whose catheter-based ultrasound devices are used to break up blood clots in legs, has been acquired by British pharmaceutical company BTG for $180 million. The ...
Please provide your email address to receive an email when new articles are posted on . HOLLYWOOD, Fla. — In patients with acute submassive pulmonary embolism, treatment with tissue plasminogen ...
The addition of IVUS to a fixed-dose catheter thrombolysis regimen failed to facilitate thrombus resolution in patients with acute iliofemoral deep vein thrombosis in the BERNUTIFUL trial. The ...
Ekos co-founder Doug Hansmann spent the past nine years developing an ultrasound catheter to help doctors quickly dissolve blood clots in the legs, arms and brain. Now after several fits and starts -- ...
Ultrasound-assisted thrombolysis was no better than standard catheter-directed delivery of alteplase when it came to clearing thrombus in patients with submassive pulmonary embolism (PE) in the SUNSET ...
BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation, a privately held medical device company located in Bothell, Washington, announced the results of DUET, the world’s first and only multi-center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback